



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/532,396	03/22/2000	Youmin Wang	6207.N CN1	8049

7590 06/04/2002

Pharmacia & Upjohn Company  
Global Intellectual Property  
301 Henrietta Street  
Kalamazoo, MI 49001

EXAMINER

BAHAR, MOJDEH

ART UNIT

PAPER NUMBER

1617

DATE MAILED: 06/04/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/532,396

Applicant(s)

WANG ET AL.

Examiner

Mojdeh Bahar

Art Unit

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 03 January 2002.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-23 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-23 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- |   |   |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____  |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) <u>3 and 11</u> . | 6) <input type="checkbox"/> Other: _____                                    |

## DETAILED ACTION

Applicant's response to the first office action of May 8, 2001, submitted January 3, 2002 (Paper No. 8) is acknowledged.

Claims 1-23 are herein examined on the merits.

### *Claim Rejections - 35 USC § 103*

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Romines et al., (USPN 5,852,195) and Suzuki et al. (USPN 5,693,337).

Romines et al., (USPN 5,852,195) teaches the pyranone compound of formula I recited in claim 1 of the instant application. Romines et al., (USPN 5,852,195) also teaches that the pyranone compound can be administered orally and parenterally. Romines et al., (USPN 5,852,195) further teaches that also parenteral suspensions of the pyranone composition can be prepared. See claims, more specifically claim 3, as well as col. 47 lines 61-65 and col.48 lines 21-47.

Romines et al., (USPN 5,852,195) does not teach the incorporation of pyranone in an emulsion. Consequently neither does it teach the employment of lecithin, an oil component, a liquid phase or weight percentages of each of the said components.

Suzuki et al. (USPN 5,693,337) teaches a stable lipid emulsion comprising water, an oil component and yolk and/or soy bean lecithin, see abstract. Furthermore Suzuki et al. (USPN 5,693,337) teaches that similar effects are expected from

dimyristoylphosphatidylcholine and dipalmitoylphosphatidylcholine and are used with yolk lecithin and/or soybean lecithin, col. 3, lines 1-12. Suzuki et al. (USPN 5,693,337) teaches the amount of emulsifying agents (i.e., lecithin) to be from 1/50 to 3 parts by weight, col. 3, lines 13-17. Moreover the oil component in Suzuki et al. (USPN 5,693,337) include mono-, di- or triglycerides whose acid components are C6-C20 saturated and/or unsaturated fatty acids and mixtures comprising at least two members of these glycerides. The amount of these oil components is not particularly restricted, but preferably ranges from 0.1 to 50%, col. 4, lines 54-67. Finally, Suzuki et al. (USPN 5,693,337) teaches that many different types of drugs including antiviral drugs can be added to the lipid emulsion, see col. 5 and col.6.

Romines et al., (USPN 5,852,195) and Suzuki et al. (USPN 5,693,337), taken together, do not teach the particular ratios of the mixture of mono-, di- and triglycerides. Moreover they do not particularly teach the weight ratio of the pyranone compound of formula I in the emulsion.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to incorporate the anti-retroviral composition of Romines et al., (USPN 5,852,195) in the lipid emulsion taught by Suzuki et al. (USPN 5,693,337). It would have further been obvious to optimize the amounts of the pyranone compound and the sub-components of the oil component of the Suzuki et al.'s emulsion.

One of ordinary skill in the art would have been motivated to incorporate the antiretroviral pyranone compound in a stable lipid emulsion such as that of Suzuki et al. (USPN 5,693,337) for its storage stability as well as potentially increased solubility. Moreover optimization of amounts is within the purview of the skilled artisan.

### ***Response to Arguments***

Applicant's arguments filed 01/03/02 have been fully considered but they are not persuasive. Applicant first argues that although the Romaines et al. patent discloses the formula I compound herein, it does not teach the incorporation of the compound in a submicron emulsion. Note that intra-conversion of dosage forms of known pharmaceutical agents is within the skill of the Artisan and therefore obvious. Moreover, it is a well-known principle that as the surface area doubles, the volume cubes. Here, micronizing the particles of the active agents increases their surface area, thereby resulting in more dissemination (i.e., surface area increases an order faster as the volume decreases) which would result in increased bioavailability of the actives *in vivo*.

Applicant then argues that Suzuki et al. requires the presence of citric acid in its emulsion. Note that the instant claims contain the open transitional phrase "comprising" which does not exclude the presence of other components, e.g., citric acid. Applicant also argues the manner in which the components in Suzuki are being mixed is unclear and he further explains the method of preparation of the instant pharmaceutical composition. Note that none of the instant claims are drawn to method of making and/or mixing. Arguments as to unclaimed limitations are moot.

Note that the incorporation of a known pharmaceutical active in an emulsion employing known excipients and pharmaceutical auxiliaries is within the purview of the skilled artisan.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mojdeh Bahar whose telephone number is (703) 305-

1007. The examiner can normally be reached on (703) 305-1007 from 8:30 a.m. to 6:30 p.m. Monday, Tuesday, Thursday and Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Minna Moezie, J.D., can be reached on (703) 308-4612. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Mojdeh Bahar  
Patent Examiner  
May 4, 2001

 RUSSELL TRAVERS  
PRIMARY EXAMINER  
GROUP 1200